Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.
Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.